Treatment of von Willebrand Disease

References

• Ruggeri, Z. M., Ware, J. L. and Ginsburg, D. (1993). von Willebrand factor. In Loscalzo, J. and Schafer, A. I. Thrombosis and Hemorrhage, Blackwell Scientific Publications, New York, NY, pp. 305–329.
   Google Scholar
• Holmberg, L. and Nilsson, I. M. (1985). von Willebrand's disease. Clinics in Hematology, 14, 461–488.
   PubMedGoogle Scholar
• Rodeghiero, F., Castaman, G. and Dini, E. (1987). Epidemiological investigation of the prevalence of von Willebrand's disease, Blood, 69, 454–459.
   PubMed Web of Science ®Google Scholar
• Miller, C. H., Lenzi, R. and Breen, C. (1987). Prevalence of von Willebrand's disease among US adults. Blood, 70, 377–383.
   Google Scholar
• Werner, E. J., Broxson, E. H., Tucker, E. L., Maanaiac, L. F., Giroux, D. S. and Abshire, T. C. (1991). Prevalence of von Willebrand disease in children: a multiethnic study. Blood, 78, 68a.
   Google Scholar
• Sadler, J. E. (1993). von Willebrand disease, in Bloom, A. and Thomas, D. P. editors Haemostasis and Thrombosis, Churchill Livingstone, London, pp. 843–857.
   Google Scholar
• Mannucci, P. M., Aberg, M., Nilsson, I. M. and Robertson, B. (1975). Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br. J. Haematol., 30, 81.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M. (1997). Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Blood, 90, 2515–2521.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Bettega, D. and Cattaneo, M. (1992). Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A. Br. J. Haematol., 82, 87–93.
   PubMed Web of Science ®Google Scholar
• Smith, T. J., Gill, J. C., Ambroso, D. R. and Hathaway, W. E. (1989). Hyponatremia and seizures in young children given DDAVP. Am J. Hematol., 31, 199–202.
   PubMed Web of Science ®Google Scholar
• Bond, L. and Bevin, D. (1988). Myocardial infarction in a patient with hemophilia A treated with DDAVP. N. Engl. J. Med., 318, 121.
   PubMed Web of Science ®Google Scholar
• Byrnes, J. J., Larcada, A. and Moake, J. L. (1998). Thrombosis following desmopressin for uremic bleeding. Am J. Hematol., 28, 63–65.
   Web of Science ®Google Scholar
• Mannucci, P. M., Lombardi, R., Bader, R., Vianello, L., Federici, A. B., Solinas, S., Mazzucconi, M. G. and Mariani, G. (1985). Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood, 66, 796–802.
   PubMed Web of Science ®Google Scholar
• Holmberg, L., Nilsson, I. M., Borge, L., Gunnarsson, M. and Sjorin, E. (1983). Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease. N. Engl. J. Med., 309, 816–821.
   PubMed Web of Science ®Google Scholar
• Fowler, W. E., Berkowitz, L. R. and Roberts, H. R. (1989). DDAVP for type IIB von Willebrand disease. Blood, 74, 1859–1860.
   PubMed Web of Science ®Google Scholar
• Mazurier, C., Gaucher, C., Jorieux, S. and Goudemand, M. (1994). The Collaborative Group. Biological effect of desmopressin in eight patients with type 2 N (‘Normandy’) von Willebrand disease. Br. J. Haematol., 88, 849–853.
   PubMed Web of Science ®Google Scholar
• Castaman, G., Lattuada, A., Mannucci, P. M. and Rodeghiero, F. (1994). Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br. J. Haematol., 89, 849–854.
   Web of Science ®Google Scholar
• Mannucci, P. M. (1998). Hemostatic drugs. N. Engl. J. Med., 339, 245–254.
   PubMed Web of Science ®Google Scholar
• Perkins, H. A. (1967). Correction of the hemostatic defects in von Willebrand disease. Blood, 30, 375–380.
   PubMed Web of Science ®Google Scholar
• Rodeghiero, F., Castaman, G., Meyer, D. and Mannucci, P. M. (1992). Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang, 62, 193–199.
   PubMed Web of Science ®Google Scholar
• Cornu, P., Larrieu, M. J., Caen, J. and Bernard, J. (1963). Transfusion studies in von Willebrand disease: effect on bleeding time and factor VIII. Br. J. Haematol., 9, 189–202.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Tenconi, P. M., Castaman, G. and Rodeghiero, F. (1992). Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood, 79, 3130–3137.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Lattuada, A. and Ruggeri, Z. M. (1994). Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood, 83, 3018–3027.
   PubMed Web of Science ®Google Scholar
• Cattaneo, M., Moia, M., Della Valle, P., Castellana, P. and Munnucci, P. M. (1989). DDAVP shortens the prolonged bleeding time of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood, 74, 1972–1975.
   PubMed Web of Science ®Google Scholar
• Castillo, R., Monteagudo, J., Escolar, G., Ordinas, A., Magallon, M. and Martin Villar, J. (1991). Hemostatic effect of normal platelet transfusion in severe von Willebrand disease. Blood, 77, 1901–1905.
   PubMed Web of Science ®Google Scholar
• Castillo, R., Escolar, G., Monteagudo, J., Aznar-Salatti, J., Reverter, J. C. and Ordinas, A. (1997). Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion, 37, 785–790.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M. (1995). Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc. Natl. Acad. Sci. USA, 92, 2428–2432.
   PubMed Web of Science ®Google Scholar
• Goudemand, J., Mazurier, C., Marey, A., Caron, C., Coupez, B., Mizon, P. and Goudemand, M. (1992). Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VII activity. Br. J. Haematol., 80, 214–221.
   PubMed Web of Science ®Google Scholar
• Menache, D., Aronson, D. L., Darr, F., Montgomery, R. and the Cooperative Study Group. (1996). Pharmacokinetics of von Willebrand factor and factor VIII in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIII synthesis. Br. J. Haematol., 94, 740–745.
   PubMed Web of Science ®Google Scholar
• Conti, M., Mari, D., Conti, E., Muggiasca, M. L. and Mannucci, P. M. (1986). Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol., 68, 282–285.
   PubMed Web of Science ®Google Scholar
• Pareti, F. I., Federici, A. B., Cattaneo, M. and Mannucci, P. M. (1990). Spontaneous platelet aggregation during pregnancy in a patient with VWD type II B can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br. J. Haematol., 75, 86–91.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Ruggeri, Z. M., Ciavarella, N., Kazatchkine, M. D. and Mowbray, J. F. (1981). Precipitating antibodies to FVIII/von Willebrand factor in von Willebrand disease: effects on replacement therapy. Blood, 57, 25–31.
   PubMed Web of Science ®Google Scholar
• Bergamaschini, L., Mannucci, P. M., Federici, A. B., Coppola, R., Guzzoni, S. and Agostoni, A. (1995). Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J. Lab. Clin. Med., 125, 348–355.
   PubMed Web of Science ®Google Scholar
• Mannucci, P. M., Tamaro, G., Narchi, G., Candotti, G., Federici, A. B., Altieri, D. and Tedesco, F. (1987). Life-threatening reaction to FVIII concentrate in a patient with severe VWD and alloantibodies to von Willebrand Factor. Eur. J. Haematol., 39, 467–470.
   PubMed Web of Science ®Google Scholar
• Biggs, R. and Matthews, J. M. (1963). The treatment of hemorrhage in von Willebrand's disease and the blood levels of factor VIII (AHG). Br. J. Haematol., 9, 203–214.
   PubMed Web of Science ®Google Scholar
• Larrieu, M. J., Caen, J. P., Vainer, M. H., Sultan, Y. and Bernard, J. (1968). Congenital bleeding disorders with long bleeding time and normal platelet count. Am. J. Med., 45, 354–359.
   PubMed Web of Science ®Google Scholar
• Green, D. and Potter, E. V. (1976). Failure of AHF concentrate to control bleeding in von Willebrand's disease. Am. J. Med., 60, 357–361.
   PubMed Web of Science ®Google Scholar
• Blatt, P. M., Brinkhous, K. M., Culp, H. R., Krauss, S. J. and Roberts, H. R. (1976). Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA, 236, 2770–2774.
   PubMed Web of Science ®Google Scholar
• Schwartz, H. P., Turecek, P. L., Pichler, L., Mitterer, A., Mundt, W., Dorner, F., Roussi, J. and Drouet, L. (1997). Recombinant von Willebrand factor. Thromb Haemostas., 78, 571–575.
   PubMed Web of Science ®Google Scholar